Curaleaf Responds to Alberta Securities Commission Decision

Curaleaf said its enhanced offer for Aurora implies approximately US$5.00 per share, which it characterizes as an 86% premium to Aurora’s unaffected approximately US$2.75 volume-weighted average share price. Curaleaf criticized Aurora for excluding it from customary diligence and said Aurora stopped using its ATM program on August 18 after Curaleaf challenged the share issuance. Curaleaf says a combination would span 17 countries, generate more than US$1.5 billion in LTM revenue and nearly US$350 million in LTM Adjusted EBITDA, with at least US$40 million in expected annual cost synergies; these are the bidder’s claims and projections.

Analysis

This is bidder advocacy, not independent evidence that the offer will close or that the claimed synergies are achievable. The ATM dispute may improve Curaleaf’s leverage with Aurora shareholders by framing the board’s process as inconsistent, but it can also harden the board’s resistance and extend the timeline. An asserted premium to an unaffected price is not a reliable measure of value if the offer currency, exchange mechanics, financing, conditions, and current trading prices change the economics.

Near term, expect event-driven volatility in both securities rather than a durable re-rating. Over 1–3 months, the key catalysts are the actual tender response, any board recommendation or revised proposal, access to diligence, and regulatory/transaction conditions. For Aurora, a failed offer could unwind takeover optionality; for Curaleaf, a deal could add scale but also expose shareholders to integration, financing, and cross-border regulatory complexity. The stated synergy figure needs diligence and execution evidence before it merits valuation credit. If consolidation proceeds, larger scale may pressure smaller cannabis operators on purchasing and distribution, but that benefit is conditional and likely gradual over 6–18 months.

Contrarian point: the public premium argument may be anchoring investors to an outdated reference price, while the central question is the value and risk of the consideration actually offered. The claimed halt in ATM issuance is also a company-reported fact to verify against filings. No clean merger-arbitrage trade is supportable without current prices and full offer terms.

Key Decisions for Investors

• Do not buy Aurora solely on the cited premium. First verify the offer consideration and conditions, current ACB/CURA prices, tender threshold, and whether the offer remains open; these determine downside if the bid fails.
• Keep Aurora on a catalyst watchlist for the next 1–3 months. Reassess only on observable changes in tender support, board process/diligence access, or a revised offer; a withdrawn or rejected proposal is the principal downside trigger.
• Avoid assigning Curaleaf material synergy value until deal terms, financing, regulatory feasibility, and integration assumptions are independently testable. A material increase in financing burden or evidence that transaction conditions are unlikely to be met would weaken the case.
• Verify Aurora’s post-August ATM activity and any subsequent share-count change in filings. Renewed issuance would dilute per-share value and undermine the bidder’s governance argument; confirmation of continued suspension would support, but not settle, that argument.